Response of Dystrophic Calcification to Intravenous Immunoglobulin

Schanz, Stefan; Ulmer, Anja; Fierlbeck, Gerhard

doi:10.1001/archderm.144.5.585

Cited by 71 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The potential mechanism in reducing calcinosis is uncertain, but may include the inhibition of activated macrophages [70]. Several case reports describe improvement in calcinosis in adults with DM and limited systemic scleroderma who had failed multiple other therapies, including warfarin, diltiazem, and extracorporeal shock wave lithotripsy [70–72]. The only case involving a child was a 10-year-old male with JDM who developed calcinosis universalis and had failed pamidronate, probenecid, cyclosporine, diltiazem, and alendronate.…”

Section: Treatmentmentioning

confidence: 99%

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

et al. 2014

View full text Add to dashboard Cite

Calcinosis is one of the hallmark sequelae of juvenile dermatomyositis (JDM), and despite recent progress in the therapy of JDM, dystrophic calcification still occurs in approximately one-third of patients. This review discusses our current, albeit limited, understanding of risk factors for the development of calcinosis in JDM, as well as approaches to assessment, and current views on its pathogenesis. Anecdotal approaches to treating calcinosis associated with JDM, including both anti-inflammatory therapies and agents aimed at inhibiting the deposition of calcium hydroxyapatite, are reviewed. An improved understanding of the pathogenesis of calcinosis, the establishment of standardized measurement tools to assess calcinosis, and randomized controlled trials employing more sensitive outcome measures are needed to develop efficacious therapies for this often disabling complication.

show abstract

Section: Treatmentmentioning

confidence: 99%

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Intravenous immunoglobulin has been tried as a therapy for dystrophic calcinosis cutis, with positive 25,26 and negative 27 results. When intravenous immunoglobulin has worked, investigators 25 have postulated that its effectiveness occurs through decreased inflammation, possibly through inhibition of macrophage function. In the present series, 6 patients received treatment with intravenous immunoglobulin; however, the results of the treatment in all 6 patients were unclear because of either the lack of follow-up data or incomplete information in the medical records.…”

Section: Intravenous Immunoglobulinmentioning

confidence: 99%

Calcinosis Cutis Occurring in Association With Autoimmune Connective Tissue Disease

Balin

Wetter²,

Andersen³

et al. 2012

Arch Dermatol

176

View full text Add to dashboard Cite

show abstract

“…Interestingly, Schanz Collagen production IL-6 IL-10 mainly suffered from debilitating dystrophic calcium deposits refractory to several therapies and causing inflammation, pain, and swelling of the index finger of her left hand: After two IVIG courses, patient's pain and inflammation subsided, and after further three more courses, she was completely symptom-free. Also, the Rodnan skin score improved after this treatment [82].…”

Section: Management Of Systemic Scleroderma With Intravenous Immunoglmentioning

confidence: 75%

Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future

et al. 2014

View full text Add to dashboard Cite

The etiology and pathogenesis of systemic sclerosis are still largely unknown, but a variety of humoral and cellular autoimmune phenomena have been documented. In addition, the rarity of the disease, the broad spectrum of clinical manifestations, and the relevant risk of severe complications as well as the highly variable disease course render its management a major challenge. Some immunomodulatory agents have been used, but no single agent has given a convincing proof of effectiveness, and treatment has remained largely symptomatic through recent years. Novel therapies are currently being tested and may have the potential of modifying the disease process and overall clinical outcome. Efficacy of intravenous immunoglobulins (IVIG) in different regimens (1-2 g/kg of body weight, administered over 2-5 consecutive days) has been described in a limited number of trials and small case series, showing benefits in skin, articular, and lung interstitial disease symptoms. However, studies on IVIG in systemic sclerosis still remain few, and further randomized controlled trials should be undertaken to assess their clinical effectiveness or define the optimal dosage and times of administration.

show abstract

Response of Dystrophic Calcification to Intravenous Immunoglobulin

Cited by 71 publications

References 16 publications

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

Calcinosis Cutis Occurring in Association With Autoimmune Connective Tissue Disease

Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future

Contact Info

Product

Resources

About